ストックスクリーナーアプリを入手
19.78
1.30%
-0.26
アフターアワーズ：
19.79
0.010
+0.05%
前日終値:
$20.04
開ける：
$20.45
24時間の取引高:
566.77K
Relative Volume:
1.22
時価総額：
$690.17M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-1.69%
1か月 パフォーマンス:
+19.16%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$18.70
$20.95
1週間の範囲:
$17.59
$20.95
52週間の値動き範囲:
$14.72
$25.58
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
名前
First Tracks Biotherapeutics Inc
セクター
電話
212-373-3000
住所
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
19.78 | 699.24M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | Leerink Partners | Outperform |
| 2026-04-24 | 開始されました | Wedbush | Outperform |
| 2026-04-23 | 開始されました | JP Morgan | Overweight |
| 2026-04-22 | 開始されました | Barclays | Overweight |
| 2026-04-21 | 開始されました | UBS | Buy |
First Tracks Biotherapeutics Inc (TRAX) 最新ニュース
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus? - simplywall.st
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell Microcap Value Benchmark Index - marketscreener.com
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell 2000 Value Benchmark - marketscreener.com
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell 2500 Value Benchmark - marketscreener.com
TRAX Forecast — Price Target — Prediction for 2027 - TradingView
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
AnaptysBio Subleases San Diego Facility to First Tracks - TipRanks
First Tracks Biotherapeutics (NASDAQ: TRAX) subleases 45,057 sq ft in San Diego - Stock Titan
AnaptysBio (NASDAQ: ANAB) subleases San Diego facility to First Tracks under master lease - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
TRAX SEC FilingsFirst Tracks Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rita Jain of First Tracks Biotherapeutics (TRAX) exercises RSUs, lifts holdings to 19,194 shares - Stock Titan
First Tracks Biotherapeutics (TRAX) director settles 6,030 RSUs into shares - Stock Titan
[Form 4] First Tracks Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (TRAX) director converts 6,030 RSUs into common shares - Stock Titan
Magda Marquet at First Tracks Biotherapeutics (TRAX) settles 6,030 RSUs - Stock Titan
First Tracks Biotherapeutics (TRAX) director converts 6,030 RSUs into common stock - Stock Titan
[Form 4/A] First Tracks Biotherapeutics, Inc. Amended Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (TRAX) director receives stock options and RSU grant - Stock Titan
First Tracks Biotherapeutics (TRAX) awards options and RSUs to director - Stock Titan
Director at First Tracks Biotherapeutics (TRAX) gets equity awards - Stock Titan
First Tracks Biotherapeutics (TRAX) director awarded options and RSUs - Stock Titan
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating - Investing.com UK
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating By Investing.com - Investing.com Canada
TRAX Initiated Coverage by First Tracks -- Rating Set to Overwei - GuruFocus
Wells Fargo Initiates First Tracks Biotherapeutics at Overweight - Moomoo
AnaptysBio earnings up next: First report as royalty company - Investing.com
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
TRAXFirst Tracks Biotherapeutics Inc Stock Price and Quote - Finviz
AnaptysBio Details Tax Treatment of Spin-Off Dividend - TipRanks
Spin-off dividend tax info posted by AnaptysBio (NASDAQ: ANAB) - Stock Titan
First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis $TRAX - MarketBeat
J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - Sahm
Zumiez Inc. to Report Fiscal 2026 First Quarter Results - The Manila Times
First Tracks Biotherapeutics (TRAX) Stock Forecast and Price Target 2026 $TRAX - MarketBeat
TRAXV SEC FilingsFirst Tracks Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
First Tracks Biotherapeutics, Inc.Ordinary Shares (NQ: TRAX - FinancialContent
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares; issuer gets no proceeds - Stock Titan
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway - TipRanks
How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets - Yahoo Finance
Form 424B3 First Tracks Biotherapeu - StreetInsider
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares - Stock Titan
First Tracks Biotherapeutics 1Q 2026: Net loss $(50.5M), Revenue $0— 10-Q Summary - TradingView
First Tracks Biotherapeutics (NASDAQ: TRAX) details Q1 loss and major post spin-off cash raises - Stock Titan
First Tracks Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
[8-K] First Tracks Biotherapeutics, Inc. Reports Material Event - Stock Titan
First Tracks Biotherapeutics Inc (TRAX) 財務データ
First Tracks Biotherapeutics Inc (TRAX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):